{"entity":{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","aka":[],"tldr":"Linked HER2 amplification to aggressive breast cancer and drove trastuzumab and later palbociclib to approval.","summary":"Dennis Slamon is Director of Clinical/Translational Research at the UCLA Jonsson Comprehensive Cancer Center and Chief of its Division of Hematology-Oncology. A medical oncologist specialising in breast cancer, his 1987 Science paper tied HER2 amplification to shorter survival and he led the clinical development of trastuzumab, later leading palbociclib development and the NATALEE adjuvant ribociclib trial. His papers include the Science report correlating relapse and survival with amplification of the HER-2/neu oncogene and the New England Journal of Medicine trial of chemotherapy plus a monoclonal antibody against HER2 in metastatic breast cancer. His work spans HER2-positive and HR-positive breast cancer and CDK4/6 inhibitors.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Dennis_Slamon","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Dennis%20J.%20Slamon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Slamon%20DJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dennis%20J.%20Slamon"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":["her2","cdk4-6"],"drugs":["trastuzumab","palbociclib","ribociclib"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["natalee"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Clinical/Translational Research, UCLA Jonsson Comprehensive Cancer Center; Chief, Division of Hematology-Oncology","institutionId":"ucla-jonsson","specialisms":["Breast cancer","HER2","CDK4/6 inhibitors"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Dennis%20J.%20Slamon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Slamon%20DJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dennis%20J.%20Slamon"}],"papers":[{"title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene","journal":"Science","year":1987,"url":"https://doi.org/10.1126/science.3798106","doi":"10.1126/science.3798106"},{"title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","journal":"New England Journal of Medicine","year":2001,"url":"https://doi.org/10.1056/NEJM200103153441101","doi":"10.1056/NEJM200103153441101"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"Slamon 1989: HER2/neu in human breast and ovarian cancer","journal":"Science","year":1989,"url":"https://doi.org/10.1126/science.2470152","doi":"10.1126/science.2470152"}]},"route":"/people/dennis-slamon/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"trial":[{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/"}],"person":[{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/"}],"paper":[{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/"},{"id":"paper-slamon-her2-amplification-science-1987","kind":"paper","name":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","route":"/key-papers/paper-slamon-her2-amplification-science-1987/"},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/"},{"id":"paper-slamon-trastuzumab-nejm-2001","kind":"paper","name":"Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer","route":"/key-papers/paper-slamon-trastuzumab-nejm-2001/"}]}}